Mersana Therapeutics (MRSN) Misses Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Citi Starts Mersana (MRSN) at Buy
November 15, 2024 4:52 AM ESTCiti analyst Yigal Nochomovitz initiates coverage on Mersana (NASDAQ: MRSN) with a Buy rating and a price target of $5.00.
The analyst comments "
MRSN expects to share initial data from the XMT-1660 (B7-H4 ADC) Ph1 by YE24. We see this readout as a... More
